No Data
Jiabiyou: Jiabiyou Biotechnology (Wuhan) Co., Ltd. 2024 Annual Performance Report Announcement
Jiabiyou Biotechnology (Wuhan) Co., Ltd. 2024 Annual Results Express Announcement
Cabio Biotech(Wuhan) (688089.SH): The net income for the fiscal year 2024 is 0.124 billion yuan, an increase of 35.25% year-on-year.
On February 27, Gelonghui reported that Cabio Biotech (Wuhan) (688089.SH) announced its performance summary for the fiscal year 2024, achieving revenue of 0.555 billion yuan, an increase of 25.06% compared to the same period last year; net income attributable to the parent company's owners was 0.124 billion yuan, an increase of 35.25% compared to the same period last year; net income attributable to the parent company owners, excluding non-recurring gains and losses, was 0.1 billion yuan, an increase of 60.57% compared to the same period last year. The growth in the company's performance during the reporting period was driven by the dual engines of domestic and international markets along with the release of new production capacity from fundraising investments. The growth in domestic business benefited from the continued release of the new national standard bonus.
Cabio Biotech(Wuhan) (688089.SH) has newly recognized Liu Yang, Yu Chao, and Tang Xiaopeng as core technical personnel.
Cabio Biotech(Wuhan) (688089.SH) announced that the company's core technical staff member, Xiao Min, has resigned for personal reasons, and after leaving...
Cabio Biotech(Wuhan) (688089.SH): Plans to invest between 15 million and 30 million yuan.
Gelonghui, January 24丨Cabio Biotech(Wuhan) (688089.SH) announced that the company plans to repurchase part of its issued ordinary shares (A shares) through centralized bidding. The repurchased shares are intended to be used for implementing a Stock-based Incentive plan at a suitable time in the future. The total amount of funds for this repurchase will not be less than 15 million RMB (inclusive) and not more than 30 million RMB (inclusive); the repurchase price will not exceed 25 RMB/share (inclusive).
Cabio Biotech(Wuhan) (688089.SH): Elect Yi Dewei to serve as the company's Director.
On December 26, Gelonghui reported that Cabio Biotech (Wuhan) (688089.SH) announced that on December 26, 2024, the company will hold the first meeting of the fourth Board of Directors, where all directors unanimously elected Mr. Yi Dewei as the chairman of the company, and Mr. Du Bin as the vice chairman, with terms effective from the approval of this Board of Directors until the term of the fourth Board of Directors expires.